血栓性血小板減少性紫斑病：パイプライン製品の分析

血栓性血小板減少性紫斑病は血液の難病で、細血管の内部で血栓が凝固し（血栓症）、血小板の数が減少するという特徴があります。主な症状としては、皮膚や粘膜への出血、錯乱、発熱、頭痛、心拍数増加、息切れ、失語症、衰弱、黄疸などが挙げられます。主な治療法には、脾臓摘出手術や免疫系抑制剤（コルチコステロイドほか）などが含まれています。

当レポートでは、世界各国での血栓性血小板減少性紫斑病治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

• 調査範囲

血栓性血小板減少性紫斑病 - 概要

血栓性血小板減少性紫斑病 - 治療薬の開発

• パイプラインの概要
• 企業別のパイプライン動向
• 大学・研究機関別のパイプライン動向
• 企業で開発中の製品
• 大学・研究機関で開発中の製品

血栓性血小板減少性紫斑病 - 治療薬の評価

• 標的別
• 作用機序別
• 投与経路別
• 分子タイプ別

血栓性血小板減少性紫斑病の治療薬開発に従事している企業

薬剤プロファイル

血栓性血小板減少性紫斑病 - 休止中のプロジェクト

血栓性血小板減少性紫斑病 - 開発が中止された製品

血栓性血小板減少性紫斑病 - 製品開発のマイルストーン

• 主なニュースとプレスリリース

付録

List of Tables

List of Tables

• Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2021
• Number of Products under Development by Companies, 2021
• Number of Products under Development by Universities/Institutes, 2021
• Products under Development by Companies, 2021
• Products under Development by Universities/Institutes, 2021
• Number of Products by Stage and Target, 2021
• Number of Products by Stage and Mechanism of Action, 2021
• Number of Products by Stage and Route of Administration, 2021
• Number of Products by Stage and Molecule Type, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by PlateletBio, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TagCyx Biotechnologies, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TargED Biopharmaceuticals BV, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, 2021
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, 2021

List of Figures

List of Figures

• Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2021
• Number of Products under Development by Companies, 2021
• Number of Products by Targets, 2021
• Number of Products by Stage and Top 10 Targets, 2021
• Number of Products by Mechanism of Actions, 2021
• Number of Products by Stage and Mechanism of Actions, 2021
• Number of Products by Routes of Administration, 2021
• Number of Products by Stage and Routes of Administration, 2021
• Number of Products by Molecule Types, 2021
• Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Drugs In Development, 2021, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to Buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

• Introduction
• Global Markets Direct Report Coverage
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
• KM Biologics Co Ltd
• Lee's Pharmaceutical Holdings Ltd
• PlateletBio
• Sanofi
• TagCyx Biotechnologies
• Takeda Pharmaceutical Co Ltd
• TargED Biopharmaceuticals BV
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
• apadamtase alfa - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• caplacizumab - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Gene Therapy for Thrombotic Thrombocytopenic Purpura - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Microlyse - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• TAGX-0004 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• ZK-001 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
• Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
• Featured News & Press Releases
• Jun 10, 2021: Lee's Pharm announces results of phase I clinical trial on the safety and antithrombotic efficacy of ANFIBATIDE
• Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
• Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise
• Mar 22, 2017: Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura
• May 25, 2016: Baxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura
• Mar 24, 2016: U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer